Morocco Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Morocco Breast Cancer Therapeutics Market Analysis

$ 3999

The Morocco breast cancer therapeutics market is projected to grow from $24 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022-2030. Some of the reasons that are responsible for the market growth are positive reimbursement policies and immunotherapy acceptance in Morocco. The market is segmented by therapy, by cancer type, and by distribution channel. Laprophan, Bristol-Myers Squibb, and Eli Lilly are some of the leading players in the Morocco breast cancer therapeutics market.

ID: IN10MAPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Morocco AUTHOR: Parul Choudhary

Buy Now

Morocco Breast Cancer Therapeutics Market Executive Analysis

The Morocco breast cancer therapeutics market size is at around $24 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. Morocco expects to spend $2.6 Bn on healthcare and social security in 2023, an increase of $418 Mn annually. The minister added that the state budget for 2023 included $463 Mn for salary increases for those employed in the healthcare industry. In relation to the nation's healthcare infrastructure, the minister disclosed that the government intends to open a lot of facilities nationwide to ensure equitable access to medical services. With $536 Mn set aside for the plan, the government would also expand access to healthcare plans to nearly four Mn needy families by paying registration fees.

In Morocco, which is experiencing an epidemiological transition characterized by a double burden brought on by the cohabitation of chronic diseases and infections, breast cancer is becoming a major public health problem. The prevalence of this condition has increased recently, most likely as a result of changes in the distribution of risk factors for breast cancer brought on by the adoption of a Western lifestyle. In Morocco, to investigate a shorter pattern, numerous teams have proposed the hypo-fractionated method. By reducing the number of meetings and increasing the dose per fraction to achieve a biological equivalency of the overall dose, this hypo-fractionated radiation shortens the duration of treatment. The ratio of breast cancer is low, around 4 Grays, according to a number of recent studies; breast adenocarcinoma would consequently exhibit high sensitivity to changes in the dose per fraction. This radiobiological defense of hypo-fractionated breast cancer radiation therapy increases its current appeal.

Market Dynamics

Market Growth Drivers

Positive reimbursement and widespread immunotherapy use are considered positive market indications for the Morocco breast cancer therapeutics market. The expansion of the market is anticipated to be fuelled by the rise in healthcare spending in Morocco as well as the increased awareness of breast cancer.

Market Restraints

Breast cancer treatment, including chemotherapy, medications, and targeted therapy, has a number of side effects after medication administration through various routes. The treatment is costly due to the increased cost of the medications used in the therapy, making treatment unaffordable for everyone and potentially driving down demand and revenue share of Morocco's breast cancer therapeutics market.

Competitive Landscape

Key Players

Laboratoire Pharmaceutique (MAR)
MC Pharma (MAR)
Génération Santé (MAR)
Laprophan (MAR)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

Every Moroccan citizen must be a part of the Assurance Maladie Obligatoire, or Compulsory Health Insurance (AMO), a mandatory basic health insurance program. All employees are covered by the social security system; those employed in the public sector receive benefits through the Caisse Nationale des Organismes de Prévoyance Sociale (CNOPS), and those employed in the private sector receive benefits through the National Social Security (CNSS). These social protection schemes are technically overseen by the National Health Insurance Agency (ANAM). Despite similar costs and benefits, ANAM reimburses some but not all novel cancer drugs, and the criteria are not always clear. For instance, the cost of using trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) is covered when treating advanced HER2-positive breast cancer, but not when treating early disease.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.